Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.
The price of Relay Therapeutics Inc (NASDAQ: RLAY) closed at $3.59 in the last session, down -2.71% from day before closing price of $3.69. In other words, the price has decreased by -$2.71 from its previous closing price. On the day, 1.09 million shares were traded. RLAY stock price reached its highest trading level at $3.74 during the session, while it also had its lowest trading level at $3.52.
Ratios:
We take a closer look at RLAY’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 20.92 and its Current Ratio is at 20.92. In the meantime, Its Debt-to-Equity ratio is 0.05 whereas as Long-Term Debt/Eq ratio is at 0.05.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Wells Fargo on April 17, 2025, initiated with a Equal Weight rating and assigned the stock a target price of $4.
On September 10, 2024, Jefferies Upgraded its rating to Buy which previously was Hold and also upped its target price recommendation from $10.60 to $16.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Jul 29 ’25 when Rahmer Peter sold 15,724 shares for $3.68 per share. The transaction valued at 57,864 led to the insider holds 377,998 shares of the business.
Rahmer Peter sold 1,359 shares of RLAY for $5,083 on Jul 28 ’25. The insider now owns 393,722 shares after completing the transaction at $3.74 per share. On Jul 29 ’25, another insider, Catinazzo Thomas, who serves as the Chief Financial Officer of the company, sold 18,380 shares for $3.68 each. As a result, the insider received 67,638 and left with 335,295 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RLAY now has a Market Capitalization of 618955520 and an Enterprise Value of -3635038. For the stock, the TTM Price-to-Sale (P/S) ratio is 74.04 while its Price-to-Book (P/B) ratio in mrq is 0.93. Its current Enterprise Value per Revenue stands at -0.435 whereas that against EBITDA is 0.011.
Stock Price History:
The Beta on a monthly basis for RLAY is 1.60, which has changed by -0.44513136 over the last 52 weeks, in comparison to a change of 0.16844666 over the same period for the S&P500. Over the past 52 weeks, RLAY has reached a high of $10.72, while it has fallen to a 52-week low of $1.77. The 50-Day Moving Average of the stock is 2.01%, while the 200-Day Moving Average is calculated to be -2.64%.
Shares Statistics:
According to the various share statistics, RLAY traded on average about 1.90M shares per day over the past 3-months and 936120 shares per day over the past 10 days. A total of 171.69M shares are outstanding, with a floating share count of 130.15M. Insiders hold about 24.51% of the company’s shares, while institutions hold 79.12% stake in the company. Shares short for RLAY as of 1755216000 were 22740377 with a Short Ratio of 11.94, compared to 1752537600 on 21520228. Therefore, it implies a Short% of Shares Outstanding of 22740377 and a Short% of Float of 16.0.
Earnings Estimates
The current market rating for Relay Therapeutics Inc (RLAY) reflects the collective analysis of 8.0 analysts closely monitoring its performance.The consensus estimate for the next quarter is -$0.36, with high estimates of -$0.05 and low estimates of -$0.53.
Analysts are recommending an EPS of between -$1.23 and -$1.9 for the fiscal current year, implying an average EPS of -$1.64. EPS for the following year is -$1.57, with 7.0 analysts recommending between -$1.24 and -$2.07.
Revenue Estimates
A total of 10 analysts have provided revenue estimates for RLAY’s current fiscal year. The highest revenue estimate was $38.4M, while the lowest revenue estimate was $8.36M, resulting in an average revenue estimate of $12.97M. In the same quarter a year ago, actual revenue was $10.01M
